SLNO - Soleno Therapeutics, Inc.

SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman

SAN FRANCISCO, May 11, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 (the "Class Period"), and suffered significant losses to submit your losses now.

May 11, 2026 09:32 AM • prnewswire.com (Hide legal announcements)

SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO

New York, New York--(Newsfile Corp. - May 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

May 05, 2026 06:51 PM • newsfilecorp.com (Hide legal announcements)

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

May 05, 2026 01:16 PM • globenewswire.com (Hide legal announcements)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.

May 05, 2026 10:33 AM • globenewswire.com

SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

SAN FRANCISCO, May 5, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 (the "Class Period"), and suffered significant losses to submit your losses now.

May 05, 2026 08:34 AM • prnewswire.com (Hide legal announcements)

Halper Sadeh LLC is Investigating Whether SLNO, APLS, HLX are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation.

May 05, 2026 08:03 AM • globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - May 5, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law

May 05, 2026 08:00 AM • feeds.newsfilecorp.com (Hide legal announcements)

DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

May 05, 2026 07:45 AM • globenewswire.com (Hide legal announcements)

Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors

LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., (“Soleno” or the “Company”) (NASDAQ: SLNO) investors off a class action on behalf of investors that bought securities between March 6, 2025 and November 4, 2025, inclusive (the “Class Period”). Soleno investors have until May 5, 2026 to file a lead plaintiff motion.

May 05, 2026 05:00 AM • globenewswire.com (Hide legal announcements)

SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

NEW YORK, May 5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

May 05, 2026 05:00 AM • prnewswire.com (Hide legal announcements)

SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO

New York, New York--(Newsfile Corp. - May 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

May 04, 2026 06:46 PM • newsfilecorp.com (Hide legal announcements)

SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options

May 04, 2026 01:47 PM • globenewswire.com (Hide legal announcements)

SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2026 lead plaintiff deadline.

May 04, 2026 08:21 AM • globenewswire.com (Hide legal announcements)

SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

May 04, 2026 08:20 AM • newsfilecorp.com (Hide legal announcements)

Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Soleno securities between March 26, 2025 and November 4, 2025, both dates inclusive (the “Class Period”).

May 04, 2026 08:00 AM • globenewswire.com (Hide legal announcements)

Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2026, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON SOLENO THERAPEUTICS, INC. (SLNO), CLICK HERE TO PARTICIPATE.

May 04, 2026 08:00 AM • businesswire.com (Hide legal announcements)

SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, May 4, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. So what: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

May 04, 2026 07:45 AM • prnewswire.com (Hide legal announcements)

SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class action and the upcoming May 5, 2026 lead plaintiff deadline. The firm urges investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 (the “Class Period”), and suffered significant losses to submit your losses now.

May 04, 2026 04:45 AM • globenewswire.com (Hide legal announcements)

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

LOS ANGELES, May 4, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

May 04, 2026 12:03 AM • prnewswire.com (Hide legal announcements)

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, May 4, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 26, 2025 and November 4, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 5, 2026.

May 03, 2026 11:06 PM • prnewswire.com (Hide legal announcements)

Soleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

$53.00 (was $52.57)

Wells Fargo

Apr 17, 2026 05:17 AM • TheFly

Soleno Therapeutics Inc. (SLNO) PT Lowered to $100 at H.C. Wainwright

$100.00 (was $38.49)

Raghuram Selvaraju · H.C. Wainwright

Mar 04, 2026 06:41 AM • StreetInsider

Soleno Therapeutics price target raised to $114 from $106 at Wells Fargo

$114.00 (was $42.48)

Derek Archila · Wells Fargo

Jan 20, 2026 06:19 AM • TheFly

Soleno Therapeutics price target raised to $120 from $110 at H.C. Wainwright

$120.00 (was $42.48)

H.C. Wainwright

Jan 20, 2026 06:17 AM • TheFly

Soleno Therapeutics price target lowered to $107 from $121 at Baird

$107.00 (was $40.14)

Robert W. Baird

Jan 13, 2026 08:41 AM • TheFly

Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research

$60.00 (was $41.89)

Wolfe Research

Jan 12, 2026 01:52 PM • TheFly

Soleno Therapeutics price target lowered to $106 from $123 at Wells Fargo

$106.00 (was $63.85)

Derek Archila · Wells Fargo

Nov 05, 2025 06:26 AM • TheFly

Soleno Therapeutics initiated with a Buy at Goldman Sachs

$125.00 (was $58.45)

Goldman Sachs

Oct 07, 2025 04:48 AM • TheFly

Soleno Therapeutics price target raised to $121 from $105 at Baird

$121.00 (was $81.57)

Brian Skorney · Robert W. Baird

Jul 11, 2025 07:18 AM • TheFly

Soleno Therapeutics price target raised to $81 from $70 at Guggenheim

$81.00 (was $70.22)

Debjit Chattopadhyay · Guggenheim

Mar 28, 2025 07:06 AM • TheFly

Soleno Therapeutics price target raised to $102 from $72 at Baird

$102.00 (was $67.39)

Robert W. Baird

Mar 27, 2025 01:13 PM • TheFly

Soleno Therapeutics price target raised to $105 from $75 at Laidlaw

$105.00 (was $67.39)

UBS

Mar 27, 2025 08:57 AM • TheFly

H.C. Wainwright Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)

$70.00 (was $50.91)

Raghuram Selvaraju · H.C. Wainwright

Dec 02, 2024 06:43 AM • StreetInsider

Soleno Therapeutics price target raised to $74 from $59 at Stifel

$74.00 (was $50.49)

Dae Gon Ha · Stifel Nicolaus

Oct 01, 2024 02:36 AM • TheFly

Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)

$59.00 (was $49.04)

Dae Gon · Stifel Nicolaus

Aug 27, 2024 07:42 AM • StreetInsider

Oppenheimer Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)

$65.00 (was $46.76)

Leland Gershell · Oppenheimer

Aug 27, 2024 07:37 AM • StreetInsider

Piper Sandler Reiterates Overweight Rating on Soleno Therapeutics Inc. (SLNO)

$93.00 (was $42.42)

Yasmeen Rahimi · Piper Sandler

May 23, 2024 04:40 AM • StreetInsider

Baird Starts Soleno Therapeutics Inc. (SLNO) at Outperform

$72.00 (was $47.64)

Brian Skorney · Robert W. Baird

May 09, 2024 12:09 PM • StreetInsider